Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: targetedmoab who wrote (8341)	11/25/2009 10:05:26 PM
From: stockdoc77	Respond to of 63288

At least two patients post their experiences on blogs. It is public knowledge, albeit a bit hard to find. The NDA would apply to investigators, but not to the patients or ancillary staff (i.e. a treating nurse in a hospital). HIPAA laws do require health care providers to maintain confidentiality, but that is an obligation we all have to our patients, not derived from any trial participation agreements. AS long as you don't disclose the patient's name, and simply discuss the clinical outcome, it is not a HIPAA violation, no more so than if I were to post that I have a patient who is currently responding to steroids for his lung injury. The current phase 1 trial is also non-blinded, it is open label and I'm not sure to what extent even the investigators are barred from speaking about results. Pennington gave a long set remarks about the first two patients as part of IMMU RD day last year, and this was before any data had been peer reviewed and released in a public form. BTW, I am a physician and as far as I know Idaho runs a ranch in Idaho.

To: targetedmoab who wrote (8341)	11/25/2009 11:39:35 PM
From: idahoranch1	Read Replies (2) \| Respond to of 63288

<<Are you the patients physician? I guess I am a little bewildered in that if you were>> I'm not a physician at all, didn't even take biology in school. << isnt it a little unethical to call a patient on a trial and then talk about results on an investment website?>> It certainly could be. I wouldn't ever call a patient if I weren't asked to by the patient. <<are you an IMMU insider? >> Nope, I live a couple of thousand miles from Morris Plains and am only a shareholder, the patients that I talk to know that upfront. << I mean if I were a patient I would be a little po'd if someone that is an investor in the company I am on a drug trial were to call me to ask how it is going.>> And given your rightful view on that, you would never get a call from me. I've been communicating with some patients and for the last month or two it's been mostly investigating/searching for things out there that they might go to when they can't get any more hPAM4. I've spent hours looking at things they've been told about and send me, and I have a couple of other posters looking and searching as well. This is the power of the internet, information. Their oncologists just don't have the time to research all this stuff. Most oncologists that treat pancreatic cancer don't know about hPAM4, and yet, there is almost NOTHING out there that gives stage lll and lV PC patients any hope. They go over this stuff we find and will (and have) taken what they think might have some possibility to their oncologist and so far have gotten good feedback. I talked to this patient about Thanksgiving and that I was thinking about posting about a couple of patients who were doing well, him included (and they communicate with each other, and that is a very good thing) and how great it is that they are doing well and having a great Thanksgiving that they weren't expected to have this year. He was OK with that. He said "If what I'm experiencing and going through helps someone else find find this trial and it helps them, I'm happy about that". Also, the patients in this trial do not have to sign confidentiality agreements, so they can disclose what they want and have. It will probably be different in the pivotal trials. I understand your view and in the context it was made in, I agree with it in that context.